Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Portfolio Pulse from Juan Spínelli
Clearmind Medicine Inc. (NASDAQ:CMND) has been granted a new U.S. patent for a compound aimed at regulating binge drinking. This patent is a significant milestone in their MEAI-based program, which targets Alcohol Use Disorder. Clearmind's patent portfolio now includes 29 patents across major markets.
August 23, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine Inc. has received a U.S. patent for its MEAI-based compound targeting binge drinking, marking a significant milestone in its development of psychedelic-derived therapeutics.
The granting of a U.S. patent for Clearmind's MEAI-based compound is a significant development, likely to positively impact the company's stock. It strengthens their intellectual property portfolio and positions them as a leader in psychedelic-derived therapeutics, particularly for Alcohol Use Disorder.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100